Innogenetics and Solvay Pharmaceuticals extend collaboration for biomarker discovery
Innogenetics announced a 2-year extension of its longstanding research collaboration with Solvay Pharmaceuticals. Since November 1997, Solvay and Innogenetics have collaborated on a joint research program to explore new targets for Solvay's drug development activities. As of 2002, the original 5-year contract was extended for 3-years with the specific aim of validating the previously identified drug targets by molecular biological and immunohistochemical means. In 2006, the collaboration was further continued and expanded towards biomarker research, exploiting Innogenetics' expertise in diagnostic assay development.
Solvay and Innogenetics have now confirmed their intention to extend the research program for another 2 years until December 2010. The program will explore potential biomarkers and develop diagnostic assays that could serve as companion diagnostic products for selected Solvay therapeutics programs. Furthermore, Innogenetics will retain rights for development of biomarkers for commercialization in diagnostic kits.
Other news from the department business & finance
